Cargando…

Limited Utility of ITPA Deficiency to Predict Early Anemia in HCV Patients with Advanced Fibrosis Receiving Telaprevir

BACKGROUND: Severe anemia is a common side effect of Pegylated Interferon + Ribavirin (PR) and Telaprevir (TVR) in hepatitis C virus (HCV) genotype 1 patients with advanced fibrosis or cirrhosis (F3–F4). Inosine triphosphatase (ITPA) genetic variants are associated with RBV- induced anemia and dose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aghemo, Alessio, Grassi, Eleonora, Rumi, Maria Grazia, D'Ambrosio, Roberta, Galmozzi, Enrico, Degasperi, Elisabetta, Castaldi, Davide, Soffredini, Roberta, Colombo, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997406/ https://www.ncbi.nlm.nih.gov/pubmed/24760000 http://dx.doi.org/10.1371/journal.pone.0095881

Ejemplares similares

Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir
por: D’Ambrosio, Roberta, et al.
Publicado: (2012)

Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients
por: Aghemo, Alessio, et al.
Publicado: (2013)

The Association of Il28b Genotype with the Histological Features of Chronic Hepatitis C Is HCV Genotype Dependent
por: D’Ambrosio, Roberta, et al.
Publicado: (2014)

Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon
por: D’Ambrosio, Roberta, et al.
Publicado: (2016)

Treatment of Patients With HCV Related Cirrhosis: Many Rewards With Very Few Risks
por: D’Ambrosio, Roberta, et al.
Publicado: (2012)

Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals
por: D’Ambrosio, Roberta, et al.
Publicado: (2021)

Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity
por: Cheroni, Cristina, et al.
Publicado: (2015)

Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients
por: Aghemo, Alessio, et al.
Publicado: (2011)

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection
por: Asselah, Tarik, et al.
Publicado: (2015)

Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis
por: Pineda-Tenor, Daniel, et al.
Publicado: (2015)

Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives
por: Degasperi, Elisabetta, et al.
Publicado: (2014)

HBV and HCV Therapy
por: Lampertico, Pietro, et al.
Publicado: (2009)

Telaprevir
Publicado: (2012)

ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection
por: Maan, Raoel, et al.
Publicado: (2015)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study
por: Aghemo, Alessio, et al.
Publicado: (2023)

Efficacy and tolerability of telaprevir (TVR)-based triple therapy in HIV/HCV-coinfected patients
por: De Los Santos, Ignacio, et al.
Publicado: (2014)

Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study
por: Flamm, Steven L., et al.
Publicado: (2014)

Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein
por: Fujita, Yuria, et al.
Publicado: (2013)

Telaprevir Experience From Turkey
por: Komur, Suheyla, et al.
Publicado: (2015)

Cutaneous Eruption due to Telaprevir
por: Falcão, Eduardo Mastrangelo Marinho, et al.
Publicado: (2015)

No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy
por: Hoffmann, Luísa, et al.
Publicado: (2015)

The rs1127354 Polymorphism in ITPA Is Associated with Susceptibility to Infertility
por: Mollaahmadi, Fahimeh, et al.
Publicado: (2018)

ITPA Related Developmental Encephalopathy: Key Role of Neuroimaging
por: Çavuşoğlu, Dilek, et al.
Publicado: (2022)

Comment to “Telaprevir Experience From Turkey”
por: Akar, Tarik, et al.
Publicado: (2015)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

Monitoring renal function during combination therapy with telaprevir in HIV/HCV co-infected patients with advanced/fibrosis cirrhosis
por: Puzzolante, Cinzia, et al.
Publicado: (2014)

ITPA Polymorphisms and the Incidence of Toxicities in Children with Acute Lymphoblastic Leukemia
por: Svasdisant, Patpetra, et al.
Publicado: (2023)

Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
por: Coppola, Nicola, et al.
Publicado: (2014)

Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study
por: Borba, Helena HL, et al.
Publicado: (2017)

Treatment of genotype one hepatitis C virus (HCV) infection in HIV co-infected patients using telaprevir based regimen
por: Siraj, Dawd S., et al.
Publicado: (2014)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

A disease spectrum for ITPA variation: advances in biochemical and clinical research
por: Burgis, Nicholas E.
Publicado: (2016)

Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment
por: Sullivan, James C, et al.
Publicado: (2012)

Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis
por: Montes, Marisa, et al.
Publicado: (2014)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Telaprevir-Induced DRESS Syndrome Associated With Salmonella typhi
por: Akar, Tarık, et al.
Publicado: (2015)

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
por: Gomes, Lenyta Oliveira, et al.
Publicado: (2018)

Identification of ITPA on chromosome 20 as a susceptibility gene for young-onset tuberculosis
por: Nakauchi, Ayaka, et al.
Publicado: (2016)

Neural stem cell–specific ITPA deficiency causes neural depolarization and epilepsy
por: Koga, Yuichiro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5eb76lvqdqperup93nu5iqbhiv